CStone Pharmaceuticals ('CStone', HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback